Corient Private Wealth LLC Grows Holdings in Omeros Corporation $OMER

Corient Private Wealth LLC lifted its stake in Omeros Corporation (NASDAQ:OMER) by 13.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 688,025 shares of the biopharmaceutical company’s stock after acquiring an additional 79,263 shares during the quarter. Corient Private Wealth LLC’s holdings in Omeros were worth $11,817,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. State of Wyoming acquired a new stake in Omeros in the 4th quarter valued at approximately $25,000. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros in the second quarter valued at approximately $32,000. Caitong International Asset Management Co. Ltd acquired a new position in Omeros during the fourth quarter worth $33,000. Tower Research Capital LLC TRC lifted its stake in Omeros by 829.6% during the second quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 11,971 shares in the last quarter. Finally, Sei Investments Co. purchased a new position in shares of Omeros during the second quarter worth $40,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on OMER. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Omeros in a research note on Wednesday, June 10th. Wall Street Zen lowered Omeros from a “buy” rating to a “hold” rating in a research note on Sunday, June 7th. Weiss Ratings cut Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 2nd. D. Boral Capital reaffirmed a “buy” rating and issued a $36.00 target price on shares of Omeros in a research report on Tuesday, April 21st. Finally, Zacks Research upgraded shares of Omeros from a “hold” rating to a “strong-buy” rating in a research note on Thursday, April 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Omeros currently has an average rating of “Moderate Buy” and an average price target of $40.33.

Insider Buying and Selling

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total value of $87,075.00. Following the sale, the director directly owned 35,067 shares of the company’s stock, valued at approximately $407,127.87. This represents a 17.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by company insiders.

Omeros Stock Performance

Shares of Omeros stock opened at $10.48 on Wednesday. Omeros Corporation has a one year low of $2.95 and a one year high of $17.65. The company has a market cap of $758.54 million, a PE ratio of 14.97 and a beta of 2.52. The business has a 50-day simple moving average of $12.01 and a 200-day simple moving average of $11.89.

Omeros (NASDAQ:OMER) last issued its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.16. The firm had revenue of $9.89 million during the quarter, compared to analyst estimates of $4.19 million. On average, sell-side analysts predict that Omeros Corporation will post -0.94 earnings per share for the current fiscal year.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.